• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Youth, Antidepressant Medications, and Type 2 Diabetes

Youth, Antidepressant Medications, and Type 2 Diabetes

May 1, 2018
Adam Strassberg, MD.
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Adam Strassberg, MD. Dr. Strassberg has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review of: Burco M et al, JAMA Pediatrics 2017;171(12):1200–1207

Over the last decade, several published studies have reported an increased risk of type 2 diabetes associated with antidepressant use in adults. But does the same hold true for children and adolescents?

This paper is the first population-based study to examine the risk of onset of type 2 diabetes with the use of antidepressants in younger patients.

Medicaid administrative claims data from California, Florida, Illinois, and New Jersey were analyzed in a cohort of 119,608 youths, ages 5–20, who initiated treatment with antidepressants from 2005 through 2009. Regression models were used to analyze the risk of onset of type 2 diabetes relative to antidepressant use, duration, and dosing.

Current use of antidepressants was associated with a 1.92 adjusted relative risk for type 2 diabetes (95% CI, 1.43–2.57). Current users of SSRIs or SNRIs had a 1.88 adjusted relative risk (95% CI 1.34–2.64), and current users of TCAs had a 2.15 adjusted relative risk (95% CI 1.06–4.36). There were no elevated risks in current users of antidepressants other than SSRIs, SNRIs, or TCAs.

For SSRIs or SNRIs, the risk of onset of type 2 diabetes increased with longer durations of exposure and with larger cumulative dosing. Compared to risk for their use for the first 90 days, there was a relative risk of 1.68 (CI 0.83–3.40) for 91–150 days of use, 2.56 (CI 1.29–5.08) for 151–210 days of use, and 2.66 (CI 1.45–4.88) for > 210 days of use.

Compared to risk after a cumulative antidepressant dose of 1 mg–1500 mg of fluoxetine hydrochloride equivalents, there is a relative risk of 1.22 (CI 0.59–2.52) for 1501 mg–3000 mg of dose equivalents, 2.17 (1.07–4.40) for 3001–4500 mg of dose equivalents, and 2.44 (1.35–4.43) for > 4500 mg of dose equivalents.

CCPR’s Take
The study suggests that long-term antidepressant use, particularly with SSRIs or SNRIs, is associated with increased risk of onset of type 2 diabetes mellitus in children and adolescents. This increased risk is particularly prominent with long-term use and higher daily doses. But the study is observational and must be interpreted with caution. Causality cannot be inferred; however, there is a correlation. Type 2 diabetes mellitus represents a rare but serious adverse outcome to discuss with patients and families, and we should vigilantly monitor for it.
Child Psychiatry
KEYWORDS antidepressants child-psychiatry psychopharmacology_tips
    Adam Strassberg, MD.

    Can Mindfulness-Based Stress Reduction Affect Symptom Outcomes in Older Adults?

    More from this author
    www.thecarlatreport.com
    Issue Date: May 1, 2018
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Psychotropic Risks in Children and Adolescents, CCPR, May/June 2018
    Informed Consent: An Ongoing Process for Focused Care
    Embracing Conflict in the Consent Process
    Considerations When Prescribing Psychotropic Medications
    Metformin to Control Antipsychotic-Induced Weight Gain in Children
    Tips for Good Medication Practice
    Youth, Antidepressant Medications, and Type 2 Diabetes
    DOWNLOAD NOW
    Featured Book
    • CMFB2e_Cover.png

      Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

      All the important facts covering child and adolescent psychopharmacology.
      READ MORE
    Featured Video
    • therapist_canstockphoto9201097.jpg
      General Psychiatry

      Using SAMe In Clinical Practice with Garrett Rossi, MD

      Read More
    Featured Podcast
    • canstockphoto17326101.jpg
      Child Psychiatry

      Recognizing Developmental Trauma Disorder in Children and Adolescents

      Whether due to COVID, conflict, climate, or common car crashes, children often lose their caregiver at the same time they experience trauma. Our podcast with Julian Ford will...

      Listen now
    Recommended
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report

    Contact

    info@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.